Pioneer Research Solutions

Running trials

• Recruiting

  A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

  NCT07535034· Phase 2· Source

• Recruiting

  A Study of Dotinurad Versus Allopurinol in Participants With Gout

  NCT07089875· Phase 3· Source

• Recruiting

  To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

  NCT06343298· Phase 2· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Source

• Recruiting

  A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT05648214· Phase 1/2· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gout2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Source

• Completed

  A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Phase 4· Source